These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 879736)

  • 41. Antibiotic susceptibility of the subspecies of Bacteroides fragilis.
    Blazevic DJ
    Antimicrob Agents Chemother; 1976 Mar; 9(3):481-4. PubMed ID: 1259403
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The in vitro responses of Bacteroides fragilis to Moxalactam, Cefotaxime, Cefmetazole, Josamycin and erythromycin.
    Soriano F; Ponte MC; Gaspar MC
    J Clin Pathol; 1982 Oct; 35(10):1166-7. PubMed ID: 6290543
    [No Abstract]   [Full Text] [Related]  

  • 43. In-vitro sensitivity tests and in-vivo efficacy of cephalosporins against Bacteroides fragilis.
    Brook I
    J Antimicrob Chemother; 1990 Jul; 26(1):158-61. PubMed ID: 2211440
    [No Abstract]   [Full Text] [Related]  

  • 44. Clindamycin resistance in anaerobic bacteria.
    Tally FP; Cuchural GJ; Bieluch VM; Jacobus NV; Malamy MH
    Scand J Infect Dis Suppl; 1984; 43():34-43. PubMed ID: 6598519
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparison of the in vitro action and interaction of cefotaxime and desacetylcefotaxime against clinical isolates of Bacteroides spp.
    Aldridge KE
    Diagn Microbiol Infect Dis; 1989; 12(1):45-50. PubMed ID: 2714072
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [In vitro activity of the oxa-beta-lactam LY 127935 against Bacteroides fragilis and other anaerobic gram-negative rods (author's transl)].
    Werner H; Krasemann C
    Infection; 1980; 8 Suppl 3():S 342-6. PubMed ID: 6447673
    [TBL] [Abstract][Full Text] [Related]  

  • 47. In vitro activity of josamycin and rosamicin against Bacteroides fragilis compared with clindamycin, erythromycin, and metronidazole.
    Santoro J; Kaye D; Levison ME
    Antimicrob Agents Chemother; 1976 Jul; 10(1):188-90. PubMed ID: 984752
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Comparative in vitro activity of 4 cephalosporins on Bacteroides fragilis].
    Castillo AM; Fernández-Crehuet M; Ocete MD; Liébana JJ; Cueto A; Maroto MC; Piédrola MG
    Med Clin (Barc); 1986 Apr; 86(15):624-6. PubMed ID: 3724274
    [No Abstract]   [Full Text] [Related]  

  • 49. Susceptibility of 114 isolates of the Bacteroides fragilis group to imipenem and eight other antimicrobial agents.
    Downes J; Andrew JH
    Pathology; 1988 Jul; 20(3):260-3. PubMed ID: 3205597
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Inhibitory and bactericidal activity of selected beta-lactam agents alone and in combination with beta-lactamase inhibitors compared with that of cefoxitin and metronidazole against cefoxitin-susceptible and cefoxitin-resistant isolates of the Bacteroides fragilis group.
    Stratton CW; Weeks LS; Aldridge KE
    Diagn Microbiol Infect Dis; 1992; 15(4):321-30. PubMed ID: 1611847
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Speed of bactericidal action of penicillin G, ampicillin, and carbenicillin on Bacteroides fragilis.
    Schoutens E; Yourassowsky E
    Antimicrob Agents Chemother; 1974 Sep; 6(3):227-31. PubMed ID: 15830467
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Susceptibility of intestinal anaerobes to new beta-lactam antibiotics.
    Bansal MB; Chuah SK; Thadepalli H
    Chemotherapy; 1984; 30(4):237-43. PubMed ID: 6744975
    [TBL] [Abstract][Full Text] [Related]  

  • 53. In-vitro activity of erythromycin against anaerobic microorganisms.
    Harvey KJ; Miles H; Hurse A; Carson M
    Med J Aust; 1981 May; 1(9):474-5. PubMed ID: 7254109
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Factors affecting the in vitro activity of cefoperazone against the Bacteroides fragilis group.
    Sutter VL; Kwok YY
    Antimicrob Agents Chemother; 1981 Dec; 20(6):723-5. PubMed ID: 6459765
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Susceptibility to cefazedone and cefazolin and production of beta-lactamase in in Bacteroides fragilis and other species of Bacteroidaceae.
    Werner H; Krasemann C; Ungerechts J
    Arzneimittelforschung; 1979; 29(2a):388-92. PubMed ID: 314805
    [No Abstract]   [Full Text] [Related]  

  • 56. Synergism between penicillin, clindamycin, or metronidazole and gentamicin against species of the Bacteroides melaninogenicus and Bacteroides fragilis groups.
    Brook I; Coolbaugh JC; Walker RI; Weiss E
    Antimicrob Agents Chemother; 1984 Jan; 25(1):71-7. PubMed ID: 6142680
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cephamycin inactivation due to enzymatic hydrolysis by beta-lactamase from Bacteroides fragilis.
    Yotsuji A; Minami S; Kakizawa H; Yasuda T; Takai A; Saikawa I; Inoue M; Mitsuhashi S
    Antimicrob Agents Chemother; 1985 Dec; 28(6):773-7. PubMed ID: 3878690
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effect of carbon dioxide on in vitro susceptibility of anaerobic bacteria to erythromycin.
    Goldstein EJ; Sutter VL; Kwok YY; Lewis RP; Finegold SM
    Antimicrob Agents Chemother; 1981 Dec; 20(6):705-8. PubMed ID: 6798927
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparison of the activity of imipenem and beta-lactams combined with sulbactam and clavulanic acid in beta-lactamase-producing strains of Bacteroides fragilis.
    Martín MA; Castillo AM; Liébana J; Marín A; Alados JC; Piédrola G
    J Hyg Epidemiol Microbiol Immunol; 1991; 35(2):189-97. PubMed ID: 1940333
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The in-vitro activity of three long-acting cephalosporins against Bacteroides fragilis, Peptostreptococcus species and Clostridium perfringens.
    Watt B; Naden MG
    J Chemother; 1989 Jul; 1(4 Suppl):106-7. PubMed ID: 16312326
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.